secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2025-10-22T23:59:59+00:00
Accession:  0001999371-25-015796
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix doses first patient in FOCUS study of intranasal oxytocin for AVP-D at MGH
--------------------------------------------------------------------------------

- First patient dosed in FOCUS study at Massachusetts General Hospital for arginine-vasopressin deficiency (AVP-D).
- Randomized, double-blind, placebo-controlled crossover pilot evaluating TNX-2900 (6 IU) and TNX-1900 (24 IU).
- Primary endpoints: markers of anxiety, depression, and socioemotional functioning; exploratory 2-week replacement on mental health.
- Study aims to generate preliminary data for future oxytocin replacement therapy in AVP-D.
- TNX-1900/TNX-2900 are intranasal Mg2+-potentiated oxytocin formulations in development for multiple conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125015796/0001999371-25-015796-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125015796/tnxp_8k-102225.htm
  HTML page:      https://secwatch.observer/filing/0001999371-25-015796

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer